India Globalization Capital Inc. (IGC): Price and Financial Metrics
IGC Price/Volume Stats
Current price | $0.35 | 52-week high | $0.52 |
Prev. close | $0.36 | 52-week low | $0.28 |
Day low | $0.34 | Volume | 118,100 |
Day high | $0.38 | Avg. volume | 167,009 |
50-day MA | $0.36 | Dividend yield | N/A |
200-day MA | $0.35 | Market Cap | 18.82M |
IGC Stock Price Chart Interactive Chart >
IGC Stock Summary
- For IGC, its debt to operating expenses ratio is greater than that reported by just 7.65% of US equities we're observing.
- IGC's price/sales ratio is 15.47; that's higher than the P/S ratio of 93.63% of US stocks.
- Revenue growth over the past 12 months for IGC PHARMA INC comes in at 135.9%, a number that bests 95.86% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to IGC PHARMA INC, a group of peers worth examining would be LMND, MGNI, CRCT, SILK, and UDMY.
- IGC's SEC filings can be seen here. And to visit IGC PHARMA INC's official web site, go to www.igcinc.us.
IGC Valuation Summary
- In comparison to the median Healthcare stock, IGC's price/sales ratio is 715.79% higher, now standing at 15.5.
- Over the past 211 months, IGC's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for IGC.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
IGC | 2023-09-22 | 15.5 | 1.5 | -1.8 | -1.6 |
IGC | 2023-09-21 | 16.8 | 1.6 | -2.0 | -1.8 |
IGC | 2023-09-20 | 16.9 | 1.6 | -2.0 | -1.8 |
IGC | 2023-09-19 | 16.8 | 1.6 | -2.0 | -1.8 |
IGC | 2023-09-18 | 17.8 | 1.7 | -2.1 | -1.9 |
IGC | 2023-09-15 | 18.8 | 1.8 | -2.2 | -2.0 |
IGC Growth Metrics
- Its year over year cash and equivalents growth rate is now at -35.68%.
- The 2 year cash and equivalents growth rate now stands at 37.84%.
- Its 2 year net income to common stockholders growth rate is now at -105.28%.

The table below shows IGC's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 0.868 | -6.417 | -13.979 |
2022-09-30 | 0.678 | -7.191 | -14.111 |
2022-06-30 | 0.532 | -7.807 | -16.013 |
2022-03-31 | 0.397 | -7.462 | -15.016 |
2021-12-31 | 0.356 | -9.08 | -11.462 |
2021-09-30 | 0.322 | -8.503 | -11.404 |
IGC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IGC has a Quality Grade of F, ranking ahead of 0.6% of graded US stocks.
- IGC's asset turnover comes in at 0.013 -- ranking 105th of 105 Wholesale stocks.
- ENS, DPZ, and SPRS are the stocks whose asset turnover ratios are most correlated with IGC.
The table below shows IGC's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.013 | 0.238 | -0.476 |
2021-03-31 | 0.031 | 0.126 | -0.440 |
2020-12-31 | 0.031 | 0.121 | -0.436 |
2020-09-30 | 0.046 | 0.090 | -0.398 |
2020-06-30 | 0.099 | 0.040 | -0.400 |
2020-03-31 | 0.129 | 0.028 | -0.410 |
India Globalization Capital Inc. (IGC) Company Bio
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader, transit mixers and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; and Serosapse for the treatment of Parkinson's disease. In addition, it offers offer extraction, distillation, tolling, and white labeling services under the Holi Hemp brand; and hemp crude extracts, hemp isolates, and hemp distillates. The company operates in the United States, India, and Hong Kong. India Globalization Capital, Inc. was founded in 2005 and is based in Potomac, Maryland.
Latest IGC News From Around the Web
Below are the latest news stories about IGC PHARMA INC that investors may wish to consider to help them evaluate IGC as an investment opportunity.
IGC Announces Results of its 2023 Annual Stockholders MeetingPOTOMAC, Md., August 21, 2023--IGC Announces Results of its 2023 Annual Stockholders Meeting |
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsPOTOMAC, Md., August 14, 2023--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate. |
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoPOTOMAC, Md., August 02, 2023--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico |
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International ConferencePOTOMAC, Md., July 18, 2023--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer’s Association International Conference. |
IGC Reports Financial Results for Fiscal Year Ended March 31, 2023POTOMAC, Md., July 12, 2023--IGC Reports Financial Results for Fiscal Year Ended March 31, 2023. |
IGC Price Returns
1-mo | 8.02% |
3-mo | 12.32% |
6-mo | 3.09% |
1-year | -23.75% |
3-year | -67.89% |
5-year | -94.57% |
YTD | 10.03% |
2022 | -67.42% |
2021 | -37.40% |
2020 | 147.62% |
2019 | 125.00% |
2018 | -72.00% |
Continue Researching IGC
Want to see what other sources are saying about India Globalization Capital Inc's financials and stock price? Try the links below:India Globalization Capital Inc (IGC) Stock Price | Nasdaq
India Globalization Capital Inc (IGC) Stock Quote, History and News - Yahoo Finance
India Globalization Capital Inc (IGC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...